PRNewsWire
27 Jul 2026, 21:33 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 Fianlimab-Libtayo trial failed to achieve statistical significance for its primary endpoint of progression-free survival. — The failure of a Phase 3 trial for a primary indication is a material setback for a drug's commercial viability and future revenue projections.
-0.80A securities class action lawsuit has been filed alleging Regeneron misled investors regarding the viability and prospects of the Fianlimab-Libtayo study. — Litigation creates potential financial liabilities and reputational risk, though it is a secondary effect of the trial failure.
-0.40Regeneron modified the Phase 3 study in April 2026 to expand the number of patients eligible for progression-free survival analysis. — Mid-study modifications to endpoints or patient pools often signal internal concerns about the original study's ability to meet its goals.
-0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities class action lawsuit following the failure of a Phase 3 clinical trial and allegations of misleading investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
